An important finding is that metformin, the first-line drug for type-2 diabetes, blocks CD39 and CD73 by increasing AMPKα phosphorylation and inhibiting HIF-α pathway to interrupt immunosuppression caused by MDSC as well as enhance the anti-tumor activity of CD8 + T cells [14]. The gene discussed is ENTPD1; the disease is neoplasm.